Promising breakthrough for transplant patients

February 27, 2013

A team led by Dr. Marie-Josée Hébert from the University of Montreal Hospital Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies – anti-LG3 – which when activated lead to severe rejection episodes associated with a high rate of organ loss. This discovery, which holds promise for organ recipients, was published in the online version of the American Journal of Transplantation.

Rejection is one of the major obstacles to . For the most part, it occurs when the recipient's immune system recognizes the transplanted organ as a foreign body that must be eliminated. However, even when there is a good donor-recipient immunologic match, the recipient's immune system can attack the transplanted organ's blood vessels. Called acute vascular rejection, this phenomenon often leads to a high rate of graft loss.

Hébert's team has characterized anti-LG3, an antibody that some patients produce to attack LG3, a protein that plays an important role in vascular repair and regeneration. "In these patients, the secretion of LG3 by the new kidney stimulates the activity of these antibodies which attack and injure the blood vessels of the transplanted organ. The net effect is that the normal healing process of the transplanted organ is hindered, if not interrupted, leading to impaired and even loss," explains Dr. Hébert.

By identifying the heightened presence of anti-LG3 antibodies in patients prior to transplantation, researchers will be able to predict the development of severe rejection episodes. "These results are quite exciting," notes Hébert, "and suggest that new therapies aimed at eliminating LG3 antibodies prior to transplantation could reduce or limit its severity."

Given that LG3 is present in all blood vessels and thus in all transplanted organs, Hébert's results could also explain rejection of other types of transplanted organ, such as the heart, lung and pancreas.

Explore further: Antibody response may lead to narrowed arteries and organ rejection

Related Stories

Green light for flu vaccine in transplant recipients

April 28, 2011

Getting vaccinated against the flu lowers kidney transplant recipients' risk of organ loss and death, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). ...

Recommended for you

Study finds mixed results for use of mesh for hernia repair

October 18, 2016

Among patients undergoing incisional hernia repair, the use of mesh to reinforce the repair was associated with a lower risk of hernia recurrence over 5 years compared with when mesh was not used, although with long-term ...

Traditional surgery style worthwhile, says piles trial

October 10, 2016

Results of a five year trial on haemorrhoids (commonly known as piles), jointly sponsored by NHS Highland and the University of Aberdeen, have this week been published in The Lancet, one of the world's oldest and best known ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Feb 27, 2013
Patent taken out Filing date Mar 8, 2011
Inventors Marie-Josee Hebert
Anti-lg3 antibodies and uses thereof
US 20130004978 A1

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.